These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30911585)

  • 1. Plasma alpha-synuclein detected by single molecule array is increased in PD.
    Ng ASL; Tan YJ; Lu Z; Ng EYL; Ng SYE; Chia NSY; Setiawan F; Xu Z; Tay KY; Prakash KM; Au WL; Tan EK; Tan LCS
    Ann Clin Transl Neurol; 2019 Mar; 6(3):615-619. PubMed ID: 30911585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
    Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
    J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease.
    Zou J; Guo Y; Wei L; Yu F; Yu B; Xu A
    Neurotherapeutics; 2020 Jul; 17(3):1104-1119. PubMed ID: 32236821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control.
    Lin WC; Lu CH; Chiu PY; Yang SY
    Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
    Chung CC; Chan L; Chen JH; Hung YC; Hong CT
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34067663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.
    Yang SY; Chiu MJ; Lin CH; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH
    J Nanobiotechnology; 2016 Jun; 14(1):41. PubMed ID: 27278241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy.
    Lee PH; Lee G; Park HJ; Bang OY; Joo IS; Huh K
    J Neural Transm (Vienna); 2006 Oct; 113(10):1435-9. PubMed ID: 16465458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using gastrocnemius sEMG and plasma α-synuclein for the prediction of freezing of gait in Parkinson's disease patients.
    Wang XY; Kang WY; Yang Q; Zhang LY; Chen SD; Liu J
    PLoS One; 2014; 9(2):e89353. PubMed ID: 24586710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in Parkinson's disease: focus on plasma α-synuclein.
    Caranci G; Piscopo P; Rivabene R; Traficante A; Riozzi B; Castellano AE; Ruggieri S; Vanacore N; Confaloni A
    J Neural Transm (Vienna); 2013 Aug; 120(8):1209-15. PubMed ID: 23328951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease.
    Emmanouilidou E; Papagiannakis N; Kouloulia S; Galaziou A; Antonellou R; Papadimitriou D; Athanasiadou A; Bozi M; Koros C; Maniati M; Vekrellis K; Ioannou PC; Stefanis L
    Parkinsonism Relat Disord; 2020 Apr; 73():35-40. PubMed ID: 32234683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α-Synuclein in Parkinson's Disease.
    Wang L; Wang G; Duan Y; Wang F; Lin S; Zhang F; Li H; Li A; Li H
    Neurodegener Dis; 2019; 19(5-6):204-210. PubMed ID: 32485710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease.
    Foulds PG; Diggle P; Mitchell JD; Parker A; Hasegawa M; Masuda-Suzukake M; Mann DM; Allsop D
    Sci Rep; 2013; 3():2540. PubMed ID: 23985836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls.
    Smith LM; Schiess MC; Coffey MP; Klaver AC; Loeffler DA
    PLoS One; 2012; 7(12):e52285. PubMed ID: 23284971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson's Disease.
    Folke J; Rydbirk R; Løkkegaard A; Salvesen L; Hejl AM; Starhof C; Bech S; Winge K; Christensen S; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
    Front Immunol; 2019; 10():2253. PubMed ID: 31616427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.
    Wang H; Atik A; Stewart T; Ginghina C; Aro P; Kerr KF; Seibyl J; Jennings D; ; Jensen PH; Marek K; Shi M; Zhang J
    Neurobiol Dis; 2018 Aug; 116():53-59. PubMed ID: 29705185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.